As director of plasma cell disorders care at The University of Kansas Health System and chair of the US Myeloma Innovations of Research Collaborative (USMIRC), Dr. Al-Ola Abdallah is primarily focused on managing and treating patients with various plasma cell disorders, including myeloma, AL amyloidosis, POEMS, solitary plasmacytoma, MGUS and smoldering myeloma. Additionally, he runs many clinical trials regarding PCD and has developed a multidisciplinary amyloidosis program that involves nephro-oncology, cardio-oncology, neurology and palliative care.
His interest in myeloma began when he joined the Myeloma Institute for Research and Therapy (MIRT) at the University of Arkansas for Medical Sciences as an assistant professor of medicine.
Partial Data by Infogroup (c) 2024. All rights reserved.